Financial Performance - Operating revenue for Q3 2023 was RMB 185,132,977, a decrease of 58.40% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2023 was RMB 21,454,125, down 70.53% year-on-year[2] - Basic earnings per share for Q3 2023 was RMB 0.02, down 71.43% year-on-year[2] - Total operating revenue for the first three quarters of 2023 was RMB 707,960,683, a decrease of 1.4% compared to RMB 716,265,980 in the same period of 2022[10] - Net profit for the first three quarters of 2023 increased significantly to RMB 89,811,290, compared to RMB 36,739,951 in the same period of 2022, representing a growth of 144.5%[10] - Basic and diluted earnings per share rose to RMB 0.09, up from RMB 0.04 in the previous year[10] Research and Development - R&D investment totaled RMB 50,730,733 in Q3 2023, a decrease of 28.58% compared to the same period last year, representing 27.40% of operating revenue[2] - The proportion of R&D investment to operating revenue increased by 11.44 percentage points in Q3 2023 compared to the same period last year[2] Cash Flow and Liquidity - Net cash flow from operating activities for the year-to-date period was RMB 1,712,208, a significant decline of 99.13% compared to the previous year[2] - Cash flow from operating activities generated a net amount of RMB 1,712,208, a decrease from RMB 196,182,795 in the same period last year[12] - Cash flow from investing activities resulted in a net outflow of RMB 35,490,426, an improvement from a net outflow of RMB 79,977,072 in the previous year[12] - Cash and cash equivalents stood at RMB 1,242,462,297, down from RMB 1,289,302,664, a decrease of 3.6%[8] - Cash and cash equivalents at the end of the period totaled RMB 1,242,462,297, slightly up from RMB 1,237,143,906 at the end of the same period last year[12] Assets and Liabilities - Total assets at the end of the reporting period were RMB 2,946,016,262, a decrease of 1.01% from the end of the previous year[2] - Total current assets amounted to RMB 1,950,086,202, a decrease of 5.7% from RMB 2,069,188,785 on December 31, 2022[8] - Total non-current assets increased to RMB 995,930,060 from RMB 906,818,487, reflecting a growth of 9.8% year-over-year[8] - Total liabilities decreased to RMB 609,240,398 from RMB 722,985,917, representing a reduction of 15.8%[9] - Shareholders' equity increased to RMB 2,336,775,864 from RMB 2,253,021,355, marking an increase of 3.7%[9] Operational Insights - The company experienced significant sales fluctuations in Q2 and Q3 2023 due to external environmental impacts, although cumulative sales remained stable[4] - The company reported a significant reduction in management expenses to RMB 39,075,379, down from RMB 55,061,168 year-over-year, reflecting a cost control strategy[10] - The company has not reported any new product developments or market expansions during this period[10] Inventory and Receivables - Accounts receivable rose to RMB 524,153,117 from RMB 506,383,690, an increase of 3.0%[8] - Inventory increased to RMB 41,127,892 from RMB 40,526,760, reflecting a growth of 1.5%[8]

关于核心技术人员离职的公告 股票代码：688505 股票简称：复旦张江 编号：临 2023-048 上海复旦张江生物医药股份有限公司 重要内容提示： 上海复旦张江生物医药股份有限公司（以下简称"公司"或"复旦张江"）核 心技术人员杨彤先生因个人原因于近日向公司提出离职申请，并已办理完成离职 手续。离职后，杨彤先生将不再担任公司任何职务； 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （一）核心技术人员的具体情况 杨彤先生，1976 年出生，中国籍，无境外永久居留权。2002 年 7 月获吉林 大学生物化学硕士学位。2002 年 7 月起，历任公司生物技术药物研发部研发人 员、副经理、经理、研发总监。 杨彤先生负责的工作已完成交接，公司生物技术药物研发部门的研究开 发及运营管理等工作均有序推进。杨彤先生的离职不会对公司的研发能力、持续 经营能力和核心竞争力产生重大不利影响，不会影响公司现有核心技术及研发项 目的工作开展。 截至本公告披露日，杨彤先生未直接或间接持有公司股份。根据公司《2021 年限制性股票激励计划》规定，其 ...

海通证券股份有限公司 关于上海复旦张江生物医药股份有限公司 核心技术人员离职的核查意见 上海证券交易所： 经中国证券监督管理委员会《关于同意上海复旦张江生物医药股份有限公司 首次公开发行股票注册的批复》（证监许可[2020]912 号）批复，上海复旦张江 生物医药股份有限公司（以下简称"上市公司"、"公司"或"发行人"）首次公开发 行股票 12,000 万股，每股面值人民币 0.1 元，每股发行价格人民币 8.95 元，募 集资金总额为人民币 107,400.00 万元，扣除发行费用后，实际募集资金净额为人 民币 97,432.39 万元。本次发行证券已于 2020 年 6 月 19 日在上海证券交易所上 市。海通证券股份有限公司（以下简称"保荐机构"或"海通证券"）担任其持续 督导保荐机构，持续督导期间为 2020 年 6 月 19 日至 2023 年 12 月 31 日。 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》等有关法律、法规要求，海通证券作为持续督导保荐机构，对公司核心技 术人员离职事项进行了专项核查，现将本次核查的情况报告如下： （三）保密情况 一、核心技术人员离职 ...

股票代码：688505 股票简称：复旦张江 公告编号：临 2023-046 （一）会议召开时间：2023 年 10 月 31 日（周二）下午 13:00-14:00 （二）会议召开地点：上证路演中心 上海复旦张江生物医药股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 10 月 24 日（周二）至 10 月 30 日（周一）16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@fd-zj.com 进 行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 上海复旦张江生物医药股份有限公司（以下简称"公司"）将于 2023 年 10 月 31 日于上海证券交易所网站（www.sse.com.cn）披露《上海复旦张江生物医药股 份有限公司 2023 年第三季度报告》。为便于广大投资者全面深入地了解公司 2023 年第三季度经营成果、财务状况及发展理念，公司计划于 2023 年 10 月 31 日 ...

上海复旦张江生物医药股份有限公司 股票代码：688505 股票简称：复旦张江 编号：临 2023-047 申 请 人：上海复旦张江生物医药股份有限公司 自愿披露关于注射用 FZ-AD005 抗体偶联剂用于治疗晚期实体瘤 获得药物临床试验申请受理通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海复旦张江生物医药股份有限公司（以下简称"公司"）于近日收到国家药 品监督管理局核准签发的《受理通知书》，注射用 FZ-AD005 抗体偶联剂（即抗 DLL3 抗体偶联 BB05，以下简称"该药物"）用于治疗晚期实体瘤的药物 I 期临 床试验申请获得受理。由于药品的研发周期长、审批环节多，容易受到一些不确 定性因素的影响，敬请广大投资者谨慎决策，注意防范投资风险。现将相关情况 公告如下： 一、 药品的基本情况 药物名称：注射用 FZ-AD005 抗体偶联剂 注册分类：治疗用生物制品 1 类 申请事项：境内生产药品注册临床试验 受 理 号：CXSL2300717 审批结论：根据《中华人民共和国行政许可法》第三十二条的规定， ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 須予披露的交易 認購中國銀行結構性存款產品 認購結構性存款產品 近日，本公司與中國銀行訂立中國銀行結構性存款產品協議 I 及中國銀行結構性存款產品協議 II，同意以 A 股公開發行所得暫時閑置募集資金向中國銀行認購總金額為人民幣 1.80 億元的結構 性存款產品。 上市規則的涵義 - 1 - 中國銀行結構性存款產品協議 本公司與中國銀行訂立之两份結構性存款產品協議（有關結構性存款產品均由本公司以 A 股公開發 行所得暫時閑置募集資金認購）的主要條款大致相同，載列如下： | 產品期限： | 協議 | | 期限 | | --- | --- | --- | --- | | | 中國銀行結構性存款產品協議 | I | 天 79 | | | 中國銀行結構性存款產品協議 | II | 78 天 | | 認購本金及預期 | 協議 | 本金 | 預期年化收益率範圍 | | 年化收益率： | 中國銀行結構性存款產品 | 人民 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 須予披露的交易 認購平安銀行結構性存款產品 認購結構性存款產品 近日，本公司與平安銀行訂立平安銀行結構性存款產品協議 I，同意以日常營運產生的自有閑置 資金向平安銀行認購總金額為人民幣 3.00 億元的結構性存款產品；並與平安銀行訂立平安銀行結 構性存款產品協議 II，同意以 A 股公開發行所得暫時閑置募集資金向平安銀行認購總金額為人民 幣 0.57 億元的結構性存款產品。 上市規則的涵義 根據上市規則第 14.22 條，平安銀行結構性存款產品協議項下的交易需合併計算。在訂立平安銀 行結構性存款產品協議時，就平安銀行結構性存款產品協議項下產品的總認購金額合計而言，一 項或多項適用百分比率（定義見上市規則第 14.07 條）超過 5%但均低於 25%，故根據上市規則第 14章，该等交易構成本公司之須予披露的交易，須遵守上市規則第14章有關申報及公告之規定， 惟獲豁免遵守獨立股東批准之規定。 概述 近日，本公司 ...

股票代码：688505 股票简称：复旦张江 公告编号：临 2023-045 上海复旦张江生物医药股份有限公司 关于参加 2023 年半年度制药及生物制品行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2023 年 09 月 07 日（周四）下午 13:00-15:00 会议召开方式：线上文字互动 线上文字互动平台：上海证券交易所上证路演中心（http://roadshow.sseinfo.com/） 投资者可于 2023 年 09 月 06 日（周三）16:00 前通过邮件、电话、传真等形 式将需要了解和关注的问题提前提供给公司。公司将在说明会上对投资者普遍 关注的问题进行回答。 上海复旦张江生物医药股份有限公司（以下简称"公司"）已于 2023 年 8 月 11 日于上海证券交易所网站（www.sse.com.cn）披露了《上海复旦张江生物医 药股份有限公司 2023 年半年度报告》。为便于广大投资者全面深入地了解公司 2023 年半年度经营成果、财务状况及发 ...

Financial Performance - The company reported a revenue of RMB 522.83 million for the first half of 2023, representing a 92.74% increase compared to RMB 271.26 million in the same period last year[6]. - Net profit attributable to shareholders was RMB 68.44 million, a significant recovery from a loss of RMB 35.97 million in the previous year[6]. - Basic earnings per share for the first half of 2023 were RMB 0.07, compared to a loss of RMB 0.03 per share in the same period last year[7]. - The company achieved a revenue of CNY 523 million during the reporting period, representing a year-on-year growth of 92.74%[43]. - The total comprehensive income for the period was RMB 68.50 million, a significant improvement from a loss of RMB 36.73 million in the previous year[140]. - The company reported a gross profit of RMB 481.25 million, with a gross margin of approximately 92%[139]. - The company reported a total cash inflow from operating activities of RMB 416,844,233, up from RMB 397,751,452 in the previous year[145]. Cash Flow and Liquidity - The company's net cash flow from operating activities was negative RMB 108.75 million, a decline from a positive RMB 59.37 million in the same period last year, indicating a 283.19% decrease[6]. - Cash and cash equivalents stood at RMB 1,231,128,499 as of June 30, 2023, indicating strong liquidity[60]. - The cash balance at the end of June 30, 2023, was RMB 1,148,276,143, compared to RMB 1,084,972,748 at the end of June 30, 2022[147]. - The company experienced a net cash decrease of RMB 39,492,994 during the period, contrasting with an increase of RMB 1,713,377 in the same period last year[147]. Research and Development - The research and development expenditure accounted for 22.68% of the operating revenue, a decrease of 16.71 percentage points from 39.39% in the previous year[7]. - Research and development expenses for the current period amounted to approximately CNY 118.59 million, representing a 10.99% increase compared to the previous year[32]. - The company has established advanced research and development platforms, including gene engineering, photodynamic technology, and nanotechnology, focusing strategically on photodynamic drugs and antibody-drug conjugates[20]. - The company has developed multiple products based on its gene engineering technology platform, including cytokines, fusion proteins, monoclonal antibodies, and antibody-drug conjugates (ADCs) to address unmet clinical needs[21]. Market and Industry Trends - The prevalence of skin diseases in China has been increasing, with approximately 150 million patients reported[12]. - The market size for broad skin disease treatment and care in China grew from RMB 300.4 billion in 2017 to RMB 471.8 billion in 2021, with a compound annual growth rate (CAGR) of 11.95%[12]. - The global pharmaceutical market is projected to grow at a CAGR of 3-6% from 2023 to 2027, potentially reaching approximately USD 1.9 trillion[12]. - The incidence of malignant tumors in China is significant, with lung cancer being the most prevalent, accounting for a large portion of new cases[15]. Product Development and Innovation - The company aims to be an innovator and leader in the biopharmaceutical industry, focusing on exploring clinical treatment gaps and providing effective therapeutic solutions[11]. - The company’s photodynamic therapy products have filled a significant treatment gap for specific areas, such as the urethra and anal canal, where effective therapies were previously lacking[17]. - The company is focusing on the clinical application of ALA-fluorescence-guided techniques for surgical procedures, particularly for brain gliomas and bladder cancer[24]. - The company aims to leverage the unique advantages of photodynamic drugs to develop new therapeutic solutions for currently untreatable diseases[23]. Corporate Governance and Management - The company has complied with all applicable provisions of the corporate governance code, except for the separation of the roles of chairman and CEO[92]. - The company aims to enhance its governance structure and establish a long-term incentive mechanism to attract and retain management and core technical personnel[79]. - The company has appointed new executives, including a new executive director and vice president, as of May 30, 2023[82]. - The audit committee reviewed the financial performance and ensured compliance with applicable accounting standards and Hong Kong listing rules[90]. Environmental Responsibility - The company invested ¥1.0397 million in environmental protection during the reporting period[96]. - The company has established a comprehensive environmental management system, including regular monitoring of wastewater and air emissions[96]. - The company has implemented strict waste management protocols, including registration with local solid waste management systems[97]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[96]. Shareholder Information - The company has a total of 38 million restricted stock options under the incentive plan, with 32.77 million shares granted in the first grant and 5.23 million shares reserved for future grants[79]. - The company reported a total of 38 million shares granted under the equity incentive plan, with 14.7 million shares becoming invalid due to unmet performance targets or employee departures[82]. - The company completed the registration of the first vesting period shares of the restricted stock incentive plan on May 12, 2023, issuing 7,572,100 A-shares[79]. - The top ten shareholders hold a total of 1,000,000,000 shares, representing approximately 97.16% of the total shares[119].

关于注销部分募集资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 股票代码：688505 股票简称：复旦张江 编号：临 2023-044 上海复旦张江生物医药股份有限公司 根据中国证监会于 2020 年 5 月 14 日出具的《关于同意上海复旦张江生物医 药股份有限公司首次公开发行股票注册的批复》（证监许可[2020]912 号），同意 公司首次公开发行股票的注册申请。公司本次公开发行人民币普通股 12,000 万 股，本次发行价格为人民币 8.95 元/股，募集资金总额为人民币 107,400.00 万元， 扣除本次发行费用人民币9,967.61万元，募集资金净额为人民币97,432.39万元。 上述募集资金已于 2020 年 6 月 12 日全部到位，并由普华永道中天会计师事务所 （特殊普通合伙）对本次发行募集资金的到账情况进行了审验，并出具了《上海 复旦张江生物医药股份有限公司首次公开发行人民币普通股 A 股验资报告》（普 根据公司披露的《上海复旦张江生物医药股份有限公司首次公开发行 A 股 股票并在科 ...